Viatris (MEX:MYL) Marketable Securities : MXN3,328 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viatris Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Viatris's Marketable Securities for the quarter that ended in Sep. 2024 was MXN3,328 Mil.

Viatris's annual Marketable Securities declined from Dec. 2021 (MXN4,796 Mil) to Dec. 2022 (MXN4,145 Mil) and declined from Dec. 2022 (MXN4,145 Mil) to Dec. 2023 (MXN3,268 Mil).

Viatris Marketable Securities Historical Data

The historical data trend for Viatris's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Marketable Securities Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

2,057.63

4,048.02

4,796.17

4,144.85

3,267.54

Viatris Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Marketable Securities	Get a 7-Day Free Trial															4,440.08	3,267.54	2,723.45	4,125.69	3,327.66

Viatris Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Viatris (MEX:MYL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Viatris Marketable Securities Related Terms

Thank you for viewing the detailed overview of Viatris's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (MEX:MYL) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

VTRS:USA 1VTRS:Italy 0A5V:UK VIA:Germany VIA:Germany VIA:Germany VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Headlines

No Headlines